Impact of a Single Intracoronary Administration of Nicorandil before Stent deployment in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019349

Enrollment

Unknown

Registered

2018-11-07

Start date

2016-03-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Group 1:bolus injection of 2ml volume of 0.9% saline

Group 2:bolus injection of 2ml volume of nicorandil (1mg/ml)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 30 to 90 years and admitted with ACS. The diagnosis of ACS was based on the coronary angiography which showed the residual diameter stenosis =75% of coronary artery. ACS includes non-ST-elevation ACS and STEMI based on episodes of chest pain and the specific ECG variations combined with myocardial enzyme changes. Unstable angina patients are also included in ACS patients without elevated levels of myocardial enzymes.

Exclusion criteria

Exclusion criteria: Patients with history of coronary artery bypass grafting (CABG), known allergy to aspirin, clopidogrel, ticagrelor or nicorandil, bleeding history within the prior 3 months, cancer or other sever comorbidity affecting the life expectancy. NSTEMI patients are not eligible for stent implantation, so they are also excluded.

Design outcomes

Primary

Measure	Time frame
soluable CD40 ligand;TNFa;hs-CRP;SOD;MDA;ICAM-1;VCAM-1;	—

Countries

China

Contacts

Public ContactNi Mei

Qilu Hospital, Shandong University

nimei999@163.com+86 18560086717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026